Presented at: World Conference on Lung Cancer Vienna, Austria August 6-9, 2022. Economic impact of delaying care with single-gene testing versus next-generation sequencing in non-small cell lung cancer. Methods: Patients serially diagnosed with advanced NSCLC were evaluated in our hospital. There seems to be growing recognition by payers that sequential testing of. The feasibility of NGS for use in advanced non-small cell lung cancer (NSCLC) patients in clinical practice has not yet been determined. Ultimately, we hope that these data are going to be helpful in increasing access to comprehensive next-generation sequencing for patients with lung cancer. However, NGS requires high-quality tumor samples and takes a long time to generate results. This might also help with payors, either private insurance companies or public health care systems, who are looking to maximize the amount of utility that they get for their health care dollars. This will support a lot of the work that we’re doing for advocacy in areas where patients don't have access to these tests. We hope to see these results utilized by advocates for lung cancer to help fuel their efforts to increase utilization of next-generation sequencing. Results showed that NGS was attributed to the lowest total testing cost per patient vs single-gene testing and resulted in the highest proportion of patients discovering a genomic alteration for which approved targeted therapies are available. She has been recipient of two research grants (2015, My First AIRC Grant for the translational project “MET-targeting in Small Cell Lung Cancer 2010, ESMO translational research fellowship award).At the 2022 World Conference on Lung Cancer, CancerNetwork ® spoke with Brandon Sheffield, MD, an anatomic and molecular pathologist at William Osler Health System in Canada, about the effects of single-gene testing vs next-generation sequencing (NGS) on costs and overall disease outcomes in patients with non–small cell lung cancer. Pasello is extensively published in peer-review journals with 75 papers (H index: 16). Main research fields are: tumor immune microenvironment and circulating biomarkers of inflammation in thoracic cancers and real world studies on oncology diagnostic-therapeutic pathways and innovative drugs access. To date, she has been the Principal Investigator of more than 30 clinical trials and translational research projects, with particular reference to new treatment targets discovery and innovative drugs development in thoracic cancers. Institutional perspective (case study): BIA within the NKI In total 172 patients were included, all stage-IV NSCLC and melanoma patients within the chosen time periods have been selected. Although the NGS technology aims to improve the effectiveness of therapies by selecting the most promising therapy, concerns are that NGS testing is expensive and that the 'benefits' are not yet in relation to these costs. Pasello is the reference medical oncologist for thoracic cancer at the Istituto Oncologico Veneto, a research and care institute. NSCLC non-small-cell lung cancer, NGS next-generation sequencing, WGS whole-genome sequencing. Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories. Giulia Pasello (MD PhD) is Assistant Professor (Ricercatore a tempo determinato B) at the Department of Surgery, Oncology and Gastroenterology, University of Padova. In order to guarantee equity in treatment, these considerations should find their application widely and rapidly.Īim of this review is offering an overview of emerging biomarkers, relative upcoming targeted drugs, and new diagnostic chances with an authors’ perspective about a real-life diagnostic-therapeutic algorithm useful for daily clinical practice. Genomic data should be than integrated in the clinical context and matched with available therapeutic options Molecular Tumor Boards (MTB) are worldwide emerging interdisciplinary groups implemented to transfer the impact of precision medicine in clinical practice. Crucial preliminary step is the selection of the best available sample before testing, aware of clinical condition and setting of disease. Nevertheless, several aspects impact on success rate of NGS in clinical practice: a multidisciplinary approach and thorough knowledge of strengths and limits of each technologic diagnostic tool are required. The increasing number of approved drugs along with next generation sequencing (NGS) technologies look out as potential revolution of biomolecular characterization of non-small-cell lung cancer (NSCLC).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |